Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
RegulatoryCRLRivoceranibCamrelizumabNegative
AI Analysis
Summary
Elevar Therapeutics received an FDA Complete Response Letter for its combination of rivoceranib and camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma. The CRL indicates the application cannot be approved in its current form and requires additional information or studies.
Outcome Details
Complete Response Letter received for rivoceranib and camrelizumab combination as first-line treatment for unresectable or metastatic hepatocellular carcinoma
Importance:8/10
Sentiment:
-0.90
FDACRLHCConcologycombination therapyfirst-line treatment
Read the original article
Published by Drugs.com New Drug Applications on July 10, 2026 6:07 AM